Cargando…
Nuclear Export in Non-Hodgkin Lymphoma and Implications for Targeted XPO1 Inhibitors
Exportin-1 (XPO1) is a key player in the nuclear export pathway and is overexpressed in almost all cancers. This is especially relevant for non-Hodgkin lymphoma (NHL), where high XPO1 expression is associated with poor prognosis due to its oncogenic role in exporting proteins and RNA that are involv...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9855521/ https://www.ncbi.nlm.nih.gov/pubmed/36671496 http://dx.doi.org/10.3390/biom13010111 |
_version_ | 1784873399804231680 |
---|---|
author | Trkulja, Kyla L. Manji, Farheen Kuruvilla, John Laister, Rob C. |
author_facet | Trkulja, Kyla L. Manji, Farheen Kuruvilla, John Laister, Rob C. |
author_sort | Trkulja, Kyla L. |
collection | PubMed |
description | Exportin-1 (XPO1) is a key player in the nuclear export pathway and is overexpressed in almost all cancers. This is especially relevant for non-Hodgkin lymphoma (NHL), where high XPO1 expression is associated with poor prognosis due to its oncogenic role in exporting proteins and RNA that are involved in cancer progression and treatment resistance. Here, we discuss the proteins and RNA transcripts that have been identified as XPO1 cargo in NHL lymphoma including tumour suppressors, immune modulators, and transcription factors, and their implications for oncogenesis. We then highlight the research to date on XPO1 inhibitors such as selinexor and other selective inhibitors of nuclear export (SINEs), which are used to treat some cases of non-Hodgkin lymphoma. In vitro, in vivo, and clinical studies investigating the anti-cancer effects of SINEs from bench to bedside, both as a single agent and in combination, are also reported. Finally, we discuss the limitations of the current research landscape and future directions to better understand and improve the clinical utility of SINE compounds in NHL. |
format | Online Article Text |
id | pubmed-9855521 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-98555212023-01-21 Nuclear Export in Non-Hodgkin Lymphoma and Implications for Targeted XPO1 Inhibitors Trkulja, Kyla L. Manji, Farheen Kuruvilla, John Laister, Rob C. Biomolecules Review Exportin-1 (XPO1) is a key player in the nuclear export pathway and is overexpressed in almost all cancers. This is especially relevant for non-Hodgkin lymphoma (NHL), where high XPO1 expression is associated with poor prognosis due to its oncogenic role in exporting proteins and RNA that are involved in cancer progression and treatment resistance. Here, we discuss the proteins and RNA transcripts that have been identified as XPO1 cargo in NHL lymphoma including tumour suppressors, immune modulators, and transcription factors, and their implications for oncogenesis. We then highlight the research to date on XPO1 inhibitors such as selinexor and other selective inhibitors of nuclear export (SINEs), which are used to treat some cases of non-Hodgkin lymphoma. In vitro, in vivo, and clinical studies investigating the anti-cancer effects of SINEs from bench to bedside, both as a single agent and in combination, are also reported. Finally, we discuss the limitations of the current research landscape and future directions to better understand and improve the clinical utility of SINE compounds in NHL. MDPI 2023-01-05 /pmc/articles/PMC9855521/ /pubmed/36671496 http://dx.doi.org/10.3390/biom13010111 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Trkulja, Kyla L. Manji, Farheen Kuruvilla, John Laister, Rob C. Nuclear Export in Non-Hodgkin Lymphoma and Implications for Targeted XPO1 Inhibitors |
title | Nuclear Export in Non-Hodgkin Lymphoma and Implications for Targeted XPO1 Inhibitors |
title_full | Nuclear Export in Non-Hodgkin Lymphoma and Implications for Targeted XPO1 Inhibitors |
title_fullStr | Nuclear Export in Non-Hodgkin Lymphoma and Implications for Targeted XPO1 Inhibitors |
title_full_unstemmed | Nuclear Export in Non-Hodgkin Lymphoma and Implications for Targeted XPO1 Inhibitors |
title_short | Nuclear Export in Non-Hodgkin Lymphoma and Implications for Targeted XPO1 Inhibitors |
title_sort | nuclear export in non-hodgkin lymphoma and implications for targeted xpo1 inhibitors |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9855521/ https://www.ncbi.nlm.nih.gov/pubmed/36671496 http://dx.doi.org/10.3390/biom13010111 |
work_keys_str_mv | AT trkuljakylal nuclearexportinnonhodgkinlymphomaandimplicationsfortargetedxpo1inhibitors AT manjifarheen nuclearexportinnonhodgkinlymphomaandimplicationsfortargetedxpo1inhibitors AT kuruvillajohn nuclearexportinnonhodgkinlymphomaandimplicationsfortargetedxpo1inhibitors AT laisterrobc nuclearexportinnonhodgkinlymphomaandimplicationsfortargetedxpo1inhibitors |